Navigation Links
Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
Date:12/6/2007

ST. PAUL, Minn., Dec. 6 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) recently announced the removal of the prescription drug Avandia(R) from its national formulary. After careful examination of clinical literature regarding the safety and efficacy of Avandia, Prime's National Pharmacy and Therapeutics (P&T) Committee has made the decision to remove the drug from its formulary. Prime's P&T Committee is a panel of pharmacists and physicians that meets quarterly and reviews drugs for Prime's formulary.

In May 2007, a meta-analysis by Nissen, et al, suggested that Avandia significantly increased the risk of heart attack. The results of this meta-analysis were also duplicated by the Food and Drug Administration (FDA) and Avandia manufacturer, GlaxoSmithKline. Consequently, in November 2007, the FDA announced that a black boxed warning for an increased risk for heart attacks in some patients would be added to Avandia's prescribing information.

Following the May publication of the Avandia meta-analysis, Prime's outcome clinicians began an in-depth analysis of Avandia utilization. An analysis of medical and pharmacy claims revealed that over 25 percent of patients on Avandia had a history of coronary artery disease or heart failure. The clinical evidence indicated that the use of Avandia in these patients may increase cardiovascular risk. Since the meta-analysis was released in May, Prime has seen a 58 percent decline in Avandia utilization.

"Prime has made this decision after a thorough analysis of the clinical literature examining the safety and efficacy of Avandia. Prime's National P&T Committee is committed to ensuring the safety and quality of Prime's formulary medications," stated Craig Mattson, Prime's Senior Director of Drug Technology Assessment and Formulary Development. "Prime takes drug safety warnings very seriously and our primary concern is the safety of our members."

Prime is committed to communicating to physicians the safety concerns surrounding Avandia and all other medications. Prime will continue to follow all market events surrounding drug safety and will make formulary changes when necessary.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 12.5 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. More proof needed of safety and quality of electronic personal health records
2. Back to School Means Backpack Safety
3. Seniors Need a Safety Plan in Face of Disasters
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. National Patient Safety Foundation Partners with Vocera Communications
6. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: